noom med glp 1 Unveils Two New Enterprise Products to Help Employers Offer, Manage, and Effectively Control GLP-1 Expenses Noom Bets Its Behavior Change

Lilly (2023) Lillys tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

Studies on semaglutide have found that weight loss tends to increase as the dose increases, and a systematic review and meta-analysis confirmed a dose-response effect, meaning the benefits shift depending on how much you take

Insufficient intrinsic factor production, common in older adults due to age-related absorption decline, can also lead to deficiency

Important Note: Pregnant individuals should avoid taking any weight loss drugs, including fat blockers or appetite suppressants

Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial